NEW YORK (GenomeWeb) – Veracyte said today that it has signed an agreement with Quest Diagnostics that will broaden access to the Afirma Gene Expression Classifier (GEC), a laboratory-developed test used to resolve indeterminate results on fine-needle-aspiration biopsies that were initially evaluated by cytopathology for potential thyroid cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.